Giant epidermoid cyst penetrating the skull: a case report and literature review.

Intracranial epidermoid cyst is a rare pseudotumor of the nervous system, accounting for 0.2%-1.8% of all intracranial tumors. It is usually located in the cerebellopontine Angle or parasellar area, with insipid onset, slow growth and usually less than 2 cm in diameter. Giant epidermoid cysts that invade the bone have rarely been reported in the literature. Herein, we report a case of giant ECs extradural to the parietal bone, penetrating the skull and continuing to expand outward. In addition, a systematic search of four authoritative databases was conducted to collect the relevant reports of giant epidermoid cyst with diameter > 5cm for the first time, and to discuss the clinical and radiographic features of patients with giant epidermoid cyst and the influence of treatment options.

MiR-320d Inhibits Progression of EGFR-Positive Colorectal Cancer by Targeting TUSC3.

Background: The mechanism of miR-320d in EGFR-positive colorectal cancer (CRC) has not been fully elucidated. The aim of the present study was to explore the molecular mechanism of miR-320d in CRC. Methods: The miRNA microarray analysis was conducted to identify differential expressed miRNAs. The expression of miR-320d was validated using quantitative real-time PCR. EGFR-positive CRC cells were transfected with miR-320d mimic and inhibitor, after which cell proliferation, migration, and invasion were assayed. The relationship between miR-320d and TUSC3 was confirmed using bioinformatics and dual-luciferase reporter gene assays. Proteins involved in signaling pathways and the epithelial-mesenchymal transition were detected with Western blot. Results: We found that the miR-320d expression is associated with tumor size and distant metastasis in colorectal cancer. Overexpression of miR-320d in EGFR-positive HCT-116 and SW480 cells decreased not only the proliferation ability but also the invasion and migration ability. In addition, miR-320d had the ability to inhibit epithelial-to-mesenchymal transition. Luciferase assays revealed that miR-320d directly targets the 3'-UTR of TUSC3. TUSC3 was downregulated by miR-320d at both the protein and mRNA levels in EGFR-positive CRC cell lines. Conclusion: Generally, our results demonstrated that miR-320d could inhibit the malignant phenotype of EGFR-positive CRC through targeting TUSC3. The miR-320d might be a potential therapeutic target for EGFR-positive CRC.

Expression and prognostic roles of PABPC1 in hepatocellular carcinoma.

BACKGROUND: Hepatocellular carcinoma (HCC) is a common malignant tumor worldwide. The present study was aimed to identify potential hub genes involved in the progression of HCC and investigate its clinical and prognostic significance. METHOD: First, the dataset GSE76427 was used to construct a co-expression network. Weighted gene co-expression network analysis (WGCNA) was used to investigate the meaningful module. Then protein-protein interaction (PPI) network analysis and Gene Set Enrichment Analysis (GSEA) were applied to study hub genes correlated with the HCC progression. The hub gene expression and their prognostic correlation were further analyzed by a series of database. Paraffin-embedded HCC tissues obtained by biopsy from 225 patients were subjected to immunohistochemistry. RESULT: Twelve co-expressed gene modules were identified using WGCNA. The pink module showed a higher correlation with overall survival years (r = 0.69, P = 0.02). Bioinformatics analysis show the real hub gene was PABPC1 and the PABPC1 mRNA expression was higher in HCC tissues compared with normal tissues. GSEA analysis indicated that PABPC1 expression was associated with P53 signaling pathway. High expression of PABPC1 was correlated with TNM stage (P = 0.004) and serum AFP (P = 0.001). High expression of PABPC1 was correlated with worse overall survival for HCC. Multivariate analysis showed that PABPC1 was an independent prognostic factor for HCC (HR = 4.137, 95%CI: 2.454-6.974, P = 0.001). CONCLUSION: In general, PABPC1 may contribute to the progression of HCC. Moreover, PABPC1 has potential to be used as prognostic markers in HCC.

Association between PPP2CA expression and colorectal cancer prognosis tumor marker prognostic study.

BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers worldwide. The aim of this study is to identify candidate genes by bioinformatics and investigate its clinical pathological characters and prognostic significance. METHOD: First, we identify differentially expressed genes (DEGs) in CRC by analyzing gene expression datasets from Gene Expression Omnibus (GEO). Then we performed a bioinformatics analysis by using Oncomine, STRING and Oncolnc databases. Gene Set Enrichment Analysis (GSEA) was performed using TCGA data set. Then, the protein expression level of PPP2CA was detected by immunohistochemistry in 196 pairs of primary colorectal cancer and corresponding non-tumor tissues. RESULT: Total 81 differential expressed genes were identified in the overlap of datasets. PPI network show the hub genes were CCND1, PPP2CA and YAP1. We investigated Oncomine databases and found that PPP2CA mRNA expression was lower in CRC tissues compared with normal tissues. Bioinformatics analysis indicated that PPP2CA expression was associated with epithelial-mesenchymal transition signaling pathway. Low expression of PPP2CA was associated with T stage, N stage, and M stage. Low expression of PPP2CA was associated with worse overall survival for CRC, and retained significance as an independent prognostic factor for CRC. CONCLUSION: PPP2CA may act as an oncogene in the progression of colorectal cancer. Moreover, PPP2CA has potential to be used as prognostic markers or therapeutic targets in CRC.